Pfizer Inc.PFENYSE
Loading
EBITDA Over TimeContracting
Percentile Rank14
3Y CAGR-28.3%
5Y CAGR+2.8%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
-28.3%/yr
vs +20.3%/yr prior
5Y CAGR
+2.8%/yr
Recent deceleration
Acceleration
-48.7pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $15.10B | -16.7% |
| 2024 | $18.13B | +89.7% |
| 2023 | $9.56B | -76.7% |
| 2022 | $41.03B | +33.2% |
| 2021 | $30.79B | +133.8% |
| 2020 | $13.17B | -30.2% |
| 2019 | $18.85B | -3.7% |
| 2018 | $19.59B | -1.3% |
| 2017 | $19.84B | +29.8% |
| 2016 | $15.29B | - |